Recently, Shanghai WD Pharmaceutical Co., Ltd. (hereinafter referred to as WD Pharma) and Boehringer Ingelheim China (hereinafter referred to as Boehringer Ingelheim) jointly announced that Boehringer Ingelheim will leverage WD Pharma's AcuSiS® technology platform to explore innovative drug delivery techniques to address the clinical dosing challenges faced by pediatric and geriatric patients, thereby improving medication compliance.
Shanghai WD Pharmaceutical Co., Ltd. has recently successfully completed a randomized, parallel, double-blind, placebo-controlled, multi-center Phase II clinical trial of WD-1603 (carbidopa/levodopa controlled-release tablets) for the efficacy and safety in patients with Parkinson's disease. The patients with early-stage Parkinson's disease were randomized to receive 4 weeks of treatment with WD-1603 25/100 mg (low dose group), WD-1603 25/150 mg (medium dose group), WD-1603 2x25/100 mg (high dose group), or placebo.
On May 27, 2022, Fudan-Zhangjiang issued an announcement stating that the company intends to cooperate with WD Pharma on WD-1603 and sign related agreements.
With the approval of the National Medical Products Administration, Shanghai WD Pharma is sponsoring a Phase II clinical trial of WD-1603 for the treatment of early-onset idiopathic Parkinson's disease using "Next-Generation Carbidopa/Levodopa Controlled-Release Tablets."
On July 12, 2021, WDpharma received the Notice of Approval for Drug Clinical Trial from the National Medical Products Administration, and the WD-1603 project has entered into Phase II clinical trials.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as "Fudan-Zhangjiang...
